States Modify PSE Rx-Only Proposals To Curb Meth Production
This article was originally published in The Tan Sheet
Executive Summary
Legislators in Kentucky debate requiring a prescription for purchase of OTC pseudoephedrine over monthly and annual limits, while Oklahoma lawmakers consider requiring pharmacists to determine a patient’s need. CHPA opposes further limits on access and promotes electronic tracking with stop-sale technology.
You may also be interested in...
Research Refutes Rx-Only Pseudoephedrine Requirements
Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.
Georgia Limits OTC Pseudoephedrine Sales To Pharmacies
Georgia lawmakers approve a new tactic to prevent the diversion of OTC pseudoephedrine products to making methamphetamine – limiting sales to pharmacies.
TheraBiogen Supports Theramax Expansion With Education Push
Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.